Dr. Mikkael Sekeres, MD

• Hematology

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Pennsylvania Perelman School Of Medicine

  Medical School, 1996

• Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study, 2017-04-14

• Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms, 2016-10-24

• Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence, 2019-09-20

• Impact of germlineCTC1alterations on telomere length in acquired bone marrow failure, 2019-03-19

• CLINICAL AND BIOLOGICAL IMPLICATIONS OF ANCESTRAL AND NON-ANCESTRALIDH1ANDIDH2MUTATIONS IN MYELOID NEOPLASMS, 2015-04-03

• FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8, and del(20q), 2009-09-15

• The novel autophagy inhibitor ROC-325 augments the anti-leukemic activity of azacitidine, 2019-07-29

• Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy, 2020-02-26

• Consequences of mutantTET2on clonality and subclonal hierarchy, 2018-05-24

• Analysis of distinctSF3B1hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia, 2020-11-03

• The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine, 2014-11-11

• Inherited and somatic defects inDDX41in myeloid neoplasms, 2015-04-23

• Clonal Dynamics of Aplastic Anemia/Paroxysmal Nocturnal Hemoglobinuria, 2019-12-28

• Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts, 2014-12-07

• Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine, 2015-09-15

• Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC), 2016-10-24

• Leukemia evolving from paroxysmal nocturnal hemoglobinuria, 2019-08-20

• Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial, 2021-08-02

• Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes, 2019-11-26

• Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multi-center, international study, 2020-03-04

• Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy, 2020-07-14

• Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q), 2017-06-26

• Recurrent genetic defects on chromosome 5q in myeloid neoplasms, 2016-12-23

• Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents, 2015-12-22

• Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia, 2020-09-07

• 250K SNP array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions ofc-Cbl, in myeloid malignancies, 2008-12-15

• Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia, 2022-02-15

• The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q), 2018-09-21

• Clonal trajectories and cellular dynamics of myeloid neoplasms withSF3B1mutations, 2021-02-18

• Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?, 2015-08-11

• IDH1/2mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors, 2018-01-16

• BCORandBCORL1mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes, 2019-01-08

• Dynamics of clonal evolution in myelodysplastic syndromes, 2016-12-19

• Single Nucleotide Polymorphism Array Lesions,TET2, DNMT3A,ASXL1andCBLMutations Are Present in Systemic Mastocytosis, 2012-08-15

• The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes, 2019-05-21

• Expansion of Effector Memory Regulatory T-cells Represents A Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome, 2012-08-08

• Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria, 2020-12-08

• Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia, 2012-06-15

• TP53mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups, 2019-01-11

• Increased CDA expression/activity in males contributes to decreased cytidine analogue half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy, 2013-01-03

• Results of a Randomized Phase 3 Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia ("SEAMLESS”), 2021-08-23

• SomaticSETBP1mutations in myeloid malignancies, 2013-07-07

• Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality Acute Myeloid Leukemia-Composite Model for Mortality Risk Estimates, 2017-09-07

• Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review, 2021-03-30

• Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review, 2022-12-05

• Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium, 2020-12-22

• Spectrum of mutations in RARS-T patients includesTET2andASXL1mutations, 2010-03-23

• A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML), 2016-02-08

• Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care, 2017-12-14

• Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML, 2017-12-16

• Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS), 2012-04-30

• Distinctive and common features of moderate aplastic anaemia, 2020-01-31

• Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy, 2017-02-08

• Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML, 2013-06-10

• Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes, 2008-08-01

• Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure A Report on Behalf of the MDS Clinical Research Consortium, 2014-11-19

• Large granular lymphocytic laeukemia after solid organ and haematopoietic stem cell transplantation, 2020-01-20

• Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies, 2018-10-12

• Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL), 2017-06-20

• A Phase 1/ 2 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia, 2019-04-16

• Mutations inDNMT3A,U2AF1, andEZH2identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1, 2018-01-10

• Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide, 2012-03-05

• Phase II Randomized Double-Blinded Study of Pracinostat in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, 2017-01-17

• Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide, 2016-08-18

• Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy, 2017-06-14

• Real-world diagnostic testing patterns for assessment of ring sideroblasts andSF3B1mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes, 2020-11-21

• A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia, 2017-06-05

• Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia, 2021-07-12